Vasculitogenic T Cells in Large Vessel Vasculitis

被引:12
作者
Watanabe, Ryu [1 ]
Hashimoto, Motomu [1 ]
机构
[1] Osaka Metropolitan Univ, Dept Clin Immunol, Grad Sch Med, Osaka, Japan
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金
日本学术振兴会;
关键词
CD4+T cells; CD8+T cells; giant cell arteritis; regulatory T cells; Takayasu arteritis; DOUBLE-BLIND TRIAL; POLYMYALGIA-RHEUMATICA; DENDRITIC CELLS; ABATACEPT CTLA-4IG; TAKAYASU ARTERITIS; GROWTH-FACTOR; TISSUE; EXPRESSION; LESIONS; RESPONSES;
D O I
10.3389/fimmu.2022.923582
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vasculitis is an autoimmune disease of unknown etiology that causes inflammation of the blood vessels. Large vessel vasculitis is classified as either giant cell arteritis (GCA), which occurs exclusively in the elderly, or Takayasu arteritis (TAK), which mainly affects young women. Various cell types are involved in the pathogenesis of large vessel vasculitis. Among these, dendritic cells located between the adventitia and the media initiate the inflammatory cascade as antigen-presenting cells, followed by activation of macrophages and T cells contributing to vessel wall destruction. In both diseases, naive CD4(+) T cells are polarized to differentiate into Th1 or Th17 cells, whereas differentiation into regulatory T cells, which suppress vascular inflammation, is inhibited. Skewed T cell differentiation is the result of aberrant intracellular signaling, such as the mechanistic target of rapamycin (mTOR) or the Janus kinase signal transducer and activator of transcription (JAK-STAT) pathways. It has also become clear that tissue niches in the vasculature fuel activated T cells and maintain tissue-resident memory T cells. In this review, we outline the most recent understanding of the pathophysiology of large vessel vasculitis. Then, we provide a summary of skewed T cell differentiation in the vasculature and peripheral blood. Finally, new therapeutic strategies for correcting skewed T cell differentiation as well as aberrant intracellular signaling are discussed.
引用
收藏
页数:8
相关论文
共 110 条
  • [1] Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis
    Adriawan, Ignatius Ryan
    Atschekzei, Faranaz
    Dittrich-Breiholz, Oliver
    Garantziotis, Panagiotis
    Hirsch, Stefanie
    Risser, Linus Maximillian
    Kosanke, Maike
    Schmidt, Reinhold Ernst
    Witte, Torsten
    Sogkas, Georgios
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (01) : 124 - 131
  • [2] Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia
    Baldini, Mattia
    Maugeri, Norma
    Ramirez, Giuseppe A.
    Giacomassi, Chiara
    Castiglioni, Alessandra
    Prieto-Gonzalez, Sergio
    Corbera-Bellalta, Marc
    Di Comite, Gabriele
    Papa, Ilenia
    Dell'Antonio, Giacomo
    Ammirati, Enrico
    Cuccovillo, Ivan
    Vecchio, Viviana
    Mantovani, Alberto
    Rovere-Querini, Patrizia
    Sabbadini, Maria Grazia
    Cid, Maria C.
    Manfredi, Angelo A.
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (03): : 854 - 865
  • [3] IFN-γ-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-γ
    Beatty, GL
    Paterson, Y
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 166 (04) : 2276 - 2282
  • [4] Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis
    Ciccia, Francesco
    Rizzo, Aroldo
    Guggino, Giuliana
    Cavazza, Alberto
    Alessandro, Riccardo
    Maugeri, Rosario
    Cannizzaro, Alessandra
    Boiardi, Luigi
    Iacopino, Domenico Gerardo
    Salvarani, Carlo
    Triolo, Giovanni
    [J]. RHEUMATOLOGY, 2015, 54 (09) : 1596 - 1604
  • [5] Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
    Cid, Maria C.
    Unizony, Sebastian H.
    Blockmans, Daniel
    Brouwer, Elisabeth
    Dagna, Lorenzo
    Dasgupta, Bhaskar
    Hellmich, Bernhard
    Molloy, Eamonn
    Salvarani, Carlo
    Trapnell, Bruce C.
    Warrington, Kenneth J.
    Wicks, Ian
    Samant, Manoj
    Zhou, Teresa
    Pupim, Lara
    Paolini, John F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (05) : 653 - 661
  • [6] Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial
    Conway, Richard
    O'Neill, Lorraine
    Gallagher, Phil
    McCarthy, Geraldine M.
    Murphy, Conor C.
    Veale, Douglas J.
    Fearon, Ursula
    Molloy, Eamonn S.
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 48 (03) : 523 - 528
  • [7] Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis
    Corbera-Bellalta, Marc
    Alba-Rovira, Roser
    Muralidharan, Sujatha
    Espigol-Frigole, Georgina
    Rios-Garces, Roberto
    Marco-Hernandez, Javier
    Denuc, Amanda
    Kamberovic, Farah
    Perez-Galan, Patricia
    Joseph, Alexandra
    D'Andrea, Annalisa
    Bondensgaard, Kent
    Cid, Maria C.
    Paolini, John F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (04) : 524 - 536
  • [8] Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis
    Corbera-Bellalta, Marc
    Planas-Rigol, Ester
    Lozano, Ester
    Terrades-Garcia, Nekane
    Alba, Marco A.
    Prieto-Gonzalez, Sergio
    Garcia-Martinez, Ana
    Albero, Robert
    Enjuanes, Anna
    Espigol-Frigole, Georgina
    Hernadez-Rodriguez, Jose
    Roux-Lombard, Pascale
    Ferlin, Walter G.
    Dayer, Jean-Michel
    Kosco-Vilbois, Marie H.
    Cid, Maria C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (06) : 1177 - 1186
  • [9] A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis
    David Carmona, F.
    Vaglio, Augusto
    Mackie, Sarah L.
    Hernandez-Rodriguez, Jose
    Monach, Paul A.
    Castaneda, Santos
    Solans, Roser
    Morado, Inmaculada C.
    Narvaez, Javier
    Ramentol-Sintas, Marc
    Pease, Colin T.
    Dasgupta, Bhaskar
    Watts, Richard
    Khalidi, Nader
    Langford, Carol A.
    Ytterberg, Steven
    Boiardi, Luigi
    Beretta, Lorenzo
    Govoni, Marcello
    Emmi, Giacomo
    Bonatti, Francesco
    Cimmino, Marco A.
    Witte, Torsten
    Neumann, Thomas
    Holle, Julia
    Schoenau, Verena
    Sailler, Laurent
    Papo, Thomas
    Haroche, Julien
    Mahr, Alfred
    Mouthon, Luc
    Molberg, Oyvind
    Diamantopoulos, Andreas P.
    Voskuyl, Alexandre
    Brouwer, Elisabeth
    Daikeler, Thomas
    Berger, Christoph T.
    Molloy, Eamonn S.
    O'Neill, Lorraine
    Blockmans, Daniel
    Lie, Benedicte A.
    Mclaren, Paul
    Vyse, Timothy J.
    Wijmenga, Cisca
    Allanore, Yannick
    Koeleman, Bobby P. C.
    Barrett, Jennifer H.
    Cid, Maria C.
    Salvarani, Carlo
    Merkel, Peter A.
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2017, 100 (01) : 64 - 74
  • [10] The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2
    Delgoffe, Greg M.
    Pollizzi, Kristen N.
    Waickman, Adam T.
    Heikamp, Emily
    Meyers, David J.
    Horton, Maureen R.
    Xiao, Bo
    Worley, Paul F.
    Powell, Jonathan D.
    [J]. NATURE IMMUNOLOGY, 2011, 12 (04) : 295 - U117